Results 11 to 20 of about 66,826 (280)

Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review

Respiratory Medicine Case Reports, 2022
Background: Tumor necrosis factor (TNF) inhibitors have been used in the treatment of cardiac sarcoidosis, infliximab being the most commonly used.
Jaleel Jerry G. Sweis, Nabil William G. Sweis, Christian Ascoli, Benjamin Levin, Boaz Avitall, Israel Rubinstein, George Kondos, Daniel A. Culver, Marc Judson, Robert Baughman, Dawood Darbar, Wonder Drake, Shiva Shahrara, Leslie T. Cooper, Jr., Nadera J. Sweiss   +14 more
doaj   +1 more source

Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis

Bioengineering, 2022
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness.
Michael Benzaquen, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga, Kristine Heidemeyer   +7 more
doaj   +1 more source

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

RMD Open, 2020
Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligible ...
Grégoire Cormier, Benoit Le Goff, Emmanuelle Dernis, Philippe Goupille, Aleth Perdriger, Theo Rispens, David Ternant, Gilles Paintaud, Emilie Ducourau, Marine Samain, Fabienne Le Guilchard, Lucia Andras, Eric Lespessailles, Thomas Armingeat, Valérie Devauchelle-Pensec, Elisabeth Gervais, Annick de Vries, Eric Piver, Céline Desvignes, Hervé Watier, Denis Mulleman   +20 more
doaj   +1 more source

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG, Sushan LI, Sha LV, Zhao HUANG, Zhe LIU, Fuqiu LI   +5 more
doaj   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal, Hunger, Matthias, Jugl, Steffen M., Karabis, Andreas, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Nash, Peter, Thom, Howard   +8 more
core   +2 more sources

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis : Fundamentals Of Care for UveitiS (FOCUS) Initiative [PDF]

, 2018
Supplemental material available at www.aaojournal.org. Supported by AbbVie, Inc., and the Fundamentals of Care for Uveitis Initiative National Faculty.
Accorinti, Massimo, Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belfort, Rubens, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chandran, Vinod, Chee, Soon Phaik, Chiquet, Christophe, Chng, Hiok Hee, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, Fundamentals of Care for Uveitis International Consensus Group, Kuffova, Lucia, Merino, Claudia Eugenia Duran, Murphy, Conor, Nascimento, Heloisa, Porto, Fernanda Belga Ottoni, Ramanan, Athimalaipet V., Rosenbaum, James T., Salah, Sawsen, Salek, Sherveen, Siak, Jay, Sonoda, Koh Hei, Steeples, Laura, Yee, Anita Chan Sook   +50 more
core   +4 more sources

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Case Reports in Gastroenterology, 2019
Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s
Taketo Suzuki, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshikazu Hirata, Yoshihide Kimura, Yuka Suzuki, Tomonori Yamada, Hironobu Tsukamoto, Takashi Mizushima, Naomi Sugimura, Takahito Katano, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki   +13 more
doaj   +1 more source